Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-03-11
2008-09-30
Afremova, Vera (Department: 1657)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100
Reexamination Certificate
active
07429387
ABSTRACT:
The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6667041 (2003-12-01), Schmidt
patent: 7001602 (2006-02-01), Schmidt
patent: 7153514 (2006-12-01), Schmidt
patent: 2004/0180065 (2004-09-01), Schmidt
patent: 2005/0048084 (2005-03-01), Schmidt
patent: 2005/0049175 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 6-183975 (1994-07-01), None
patent: 8-511537 (1996-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 99/03483 (1999-01-01), None
Amarenco, Pour la pratique, Lae Revue du Praticien (Paris) 1995, 343-345, 45, France and abstract in English.
Araki et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, Japan.
Bulau, Therapeutische Perspektiven mit Botulinumtoxin Type A., Neurologie und rehabilitation, 1997, 55-56, Germany.
Doggweiler et al., Botox-Induced Prostatic Involution, The Prostate, 1998, 44-50, vol. 37, University of Colorado Health Science Center, Denver, CO, USA.
Dykstra et al., Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients, J Urol, May 1998, 919-922, vol. 139, Departments of Physical Medicine and Rehabilitation and Urologic Surgery, University of Minnesota Hospital and Clinic, Minneapolis Minnesota, USA.
Fowler et al., Mytonic-Like EMG Activity of the Urethral Sphincter in Women with Urinary Retention and the Use of Botulinum Toxin to Treat this Disorder, Neurophysiologie Clinique, 1990, 19s, vol. 20, Department of Uro-Neurology, National Hospital for Nervous Diseases, Queen Square and Urology Departments, The London Hospital and the Middlesex Hospital United Kingdom.
Fowler et al., Botulinum Toxin in the Treatment of Chronic Urinary Retention in Women, British Journal of Urology, 1992, 387-389, vol. 70, British Journal of Urology, United Kingdom.
Maria et al., Relief by botulinum toxin of voiding dysfunction due to prostatitis, LANCET (North American Edition), 1998, 625, vol. 352, Departments of Surgery, Urology and Neurology, Catholic University of Rome, Rome, USA.
Harrison, Principles of Internal Medicine, 1987, 196-197, 11th Edition, McGraw-Hill Book Company, New York, New York, USA.
Jankovic, Botulinum toxin in movement disorders, Current Opinion in Neurology, 1994, 358-366, vol. 7, Baylor College of Medicine, Houston, Texas, USA.
Jankovic, Therapeutic uses of Botulinum, The New England Journal of Medicine, 1991, 1186-1194, vol. 324 No. 17, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
Karp, et al., Therapeutic Effects of Botulinum Toxins, Handbook of Natural Toxins; Bacterial Toxins and Virulence Factors in Disease, 1995, 1-22, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Punch, Gynaecological, and non-gynaecological, chronic pelvic pain, The Lancet, Feb. 21, 1998, 607, vol. 351, Department of OB/BYN, University of Michigan Medical Center, Women's Hospital, Ann Arbor, Michigan, USA.
Steinhardt et al., Botulinum Toxin Novel Treatment for Dramatic Urethral Dilation Associated with Dysfunctional Voiding, The Journal of Urology, 1997, 190-191, vol. 158, American Urological Association, Inc., St. Louis, Missouri, USA.
Zwergel, et al. Bladder Dysfunction in Disseminated Encephalomyelitis-Drug Therapy and Interventional Methods, Fortschritte Der Neurologie Psychiatrie, 1995, 495-503, vol. 63, Neurologische Klinik der Universitat des Saarlandes, Homburg/Saar, Germany.
Grise, Phillippe, Affidavit, Sep. 26, 2006.
Grosse, Joachim, Affidavit, Sep. 25, 2006.
Carl, Stefan, Affidavit, Sep. 26, 2006.
E. Shapiro et al., “Quantifying the Smooth Muscle Content of the Prostate . . . ”, The Journal of Urology 147 (1992), pp. 1167 to 1170.
G.E. Borodic and L.B. Pearce, “New Concepts in Botulinum Toxin Therapy”, Drug Safety 11 (1994), pp. 145-152.
Internet presentation on prostate disorders and the anatomy of the prostate/bladder: http://www.familydoctor.co.uk/htdocs/PROSTATE/PROSTATE—specimen.html (printed on Dec. 11, 2006).
Internet presentation of prostatitis: http://www.urology-health.org/adult/index.cfm?cat=07&topic=15 (printed on Dec. 11, 2006).
Entry for “benigne Prostatahyperblasie” in Pschyrembel, klinisches Worterbuch (257.Auflage, 1994).
Martinez Pineiro et al., “Pelvic Plexus Denervation in Rats Causes Morphologic and Functional Changes of the Prostate”, The Journal of Urology 150 (1993), pp. 215-218.
Amarenco, “Evaluation et Traitement des Dysfonctionnements Vesico-Sphincteriens Neurogenes” Annales d'Urologie 27(1993) pp. 313-320.
Beleggia et al., Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
* Bruschini et al., “Neurologic Control of Prostatic Secretion in the Dog”;Invest. Urol., 15(4):288-290 (Jan. 1978).
* Downie et al., “Evidence for a Spinal Site of Action of Clonidine on Somatic and Viscerosomatic Relfex Activity Evoked on the Pudendal Nerve in Cats”;J. Pharmacol. Exp. Ther., 246(1):352-358 (May 1988).
* Dykstra et al., “Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study”;Arch. Phys. Med. Rehabil., 71:24-26 (Jan. 1990).
Fowler et al., British J of Urol., 1992, 70: 387-389.
* Håkanson et al., “Multiple Tachykinin Pools in Sensory Nerve Fibres in the Rabbit Iris”;Neuroscience, 21(3):943-950 (1987).
* Higgins et al., “Studies on the Structure and Intrinsic Innervation of the Normal Human Prostate”;Prostate Suppl., 2:5-16 (1989).
* Ishizuka et al., “Urodynamic Effects of Intravesical Resiniferatoxin and Capsaicin in Conscious Rats With and Without Outflow Obstruction”;J. Urology, 154:611-616 (Aug. 1995)+.
* Joo et al., “Initial North American Experience with Botulinum Toxin Type A for Treatmetn of Anismus”;Dis. Colon. Rectum, 39(10):1107-1111 (Oct. 1996).
* Lepor “Role of Long-Acting Selective Alpha-1 Blockers in the Treatment of Benign Prostatic Hyperplasia”;Urol. Clin. North Am., 17(3):651-658 (Aug. 1990).
* Maggi et al., “Cystometric Evidence That Capsaicin-Sensitive Nerves Modulate the Afferent Branch of Micturition Reflex in Humans”;J. Urol., 142:150-154 (Jul. 1989).
* Mocchetti, “Pharmacology of Neuronal Gene Expression”;Pharmacol. Res., 21(Suppl. 2):85-95 (1989).
Nanninga, John B., Oxins (1993) p. 589-590.
* Schurch et al.,J. Urol., 155:1023-1029 (1996).
* Tim et al.,Botulinum Toxin Therapy, 9(6):327-332 (1992).
Medical Pharmacology at a Glance, Blackwell Scientific Publications, 1987- p. 18-19.
1996 MIMS Annual, Australian Edition. The entry for Botulinum Toxin is located at 5-372.
U.S. Appl. No. 11/925,938, filed Oct. 27, 2007, Schmidt.
U.S. Appl. No. 11/925,942, filed Oct. 27, 2007, Schmidt.
U.S. Appl. No. 11/925,945, filed Oct. 27, 2007, Schmidt.
“AFUD Prostate Cancer Treatment: Treatment”; American Foundation for Urologic Disease; (at least as early as Aug. 5, 2003).
“Continence Management”; The Prostate Cancer Charity; (at least as early as Aug. 8, 2003); 6 pp.
“Inconsistence and the Prostate”; Phoenix5; (at least as early as Aug. 5, 2003); 11 pp.
Afremova Vera
Sheridan & Ross P.C.
The Regents of the University of Colorado
LandOfFree
Use of botulinum toxin therapy for treatment of recalcitrant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of botulinum toxin therapy for treatment of recalcitrant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of botulinum toxin therapy for treatment of recalcitrant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3979255